Post by ValueTrust Financial Advisors

ValueTrust supported Xlife Sciences AG as valuation advisor in the context of the valuation of selected project companies as part of the Valuation Report 2025.   In this role, we performed the valuation of selected portfolio companies based on the risk-adjusted net present value (rNPV) methodology and assessed underlying business plans, taking into account current operational progress, market conditions, and project-specific developments.   For more information: https://lnkd.in/dRhm6bB4 #ValueTrust #financialexperts #valuation #advisory #lifesciences #valuationreport #capitalmarkets